drugset
drugset / Trial / NCT04834856

Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

NCT04834856 ↗

Phase 2 Completed 12 enrolled Molecular Partners AG
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will investigate how ensovibep is distributed throughout the body, the viral clearance and the tolerability of ensovibep in patients with symptomatic COVID-19 disease

Timeline

Start
2021-04-01
Primary completion
2021-08-20
Completion
2021-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ensovibep Protein / enzyme biologic — Other

Indications

COVID-19